DBV Technologies S.A. (DBVT) vs Ginkgo Bioworks (DNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ginkgo Bioworks (DNA) has outperformed DBV Technologies S.A. (DBVT) over the past year, losing 8.7% versus a loss of 34.4%. Over five years, DBVT leads with a +50.3% price change compared with -98.5% for DNA. DBV Technologies S.A. is the larger company by market cap ($566.8 million vs $483.5 million), about 1.2 times the size.
Ginkgo Bioworks converts more of its revenue into profit, with a net margin of -183.8% versus -2607.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DBVT | DNA |
|---|---|---|
| Share price | $9.02 | $7.46 |
| Market cap | $566.82M | $483.54M |
| 1-day change | -4.25% | -9.02% |
| YTD return | -52.95% | -10.23% |
| 1-year return | -34.40% | -8.69% |
| 5-year return | +50.33% | -98.45% |
| EPS (TTM) | $-3.00 | $-4.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.64M | $170.16M |
| Revenue growth (YoY) | +35.77% | -25.06% |
| Net income (latest FY) | $-146.95M | $-312.76M |
| Operating margin | -2609.23% | -185.29% |
| Net margin | -2607.29% | -183.81% |
| 52-week high | $26.19 | $18.22 |
| 52-week low | $8.63 | $5.37 |
| Distance from 52-week high | -65.55% | -59.06% |
| Analyst consensus | buy | underperform |
| Avg. price target upside | +305.10% | +7.24% |
| Average volume | 352.88K | 2.53M |
| Shares outstanding | 62.84M | 53.94M |
| Employees | 179 | 485 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNA has outperformed DBVT by 25.7 percentage points over the past year.
- Ginkgo Bioworks is more profitable, keeping -183.8 cents of every revenue dollar as net income versus -2607.3 cents for DBV Technologies S.A..
- DBV Technologies S.A. grew revenue faster in its latest fiscal year (+35.77% vs -25.06%).
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 179 employees
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
DBVT vs DNA FAQ
Which is bigger, DBV Technologies S.A. or Ginkgo Bioworks?
DBV Technologies S.A. (DBVT) is larger, with a market capitalization of $566.82M compared with $483.54M for Ginkgo Bioworks (DNA).
Which stock has performed better over the past year, DBVT or DNA?
DNA returned -8.69% over the past 12 months, compared with -34.40% for DBVT (price return, excluding dividends). Past performance does not predict future results.
Are DBV Technologies S.A. and Ginkgo Bioworks in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.